Home >> Tag Archives: Cynvenio Biosystems—

Tag Archives: Cynvenio Biosystems—

Cynvenio offers cfDNA purification upgrade

Feb. 16, 2016—Cynvenio Biosystems announced the availability of the Concordia cell-free DNA purification sample preparation upgrade for its multitemplate analysis LiquidBiopsy platform. When coupled with Thermo Fisher Scientific’s Ion Torrent next-generation sequencing systems, Cynvenio’s workflow provides a comprehensive molecular characterization of tumor cell DNA for cancer research samples from a standard blood draw. The Concordia option, which consists of a ...

Read More »

Trial starts for breast cancer liquid biopsy test

Jan. 21, 2016—Diagnostics company Cynvenio Biosystems and Korean biotech firm ATGen Global have launched a pilot study to evaluate a new method for early detection of cancer in women who have completed treatment for triple-negative breast cancer and show no radiographic signs of metastases. The new study will use Cynvenio’s ClearID test, based on its liquid biopsy technology, in combination ...

Read More »

Cynvenio announces new PD-L1 test

Oct. 29, 2015—Cynvenio Biosystems announced it has developed, validated, and fully implemented a Programmed Death-Ligand 1 assay for circulating tumor cells obtained via its liquid biopsy technology for several tumor subtypes. Unlike most circulating tumor cell technologies which enumerate CTCs, Cynvenio said its multitemplate approach allows for simultaneous isolation of cell-free DNA and CTCs that can be both evaluated for ...

Read More »